Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$4.70 -0.4%	$5.23	$1.67 ▼ $7.29	$420.10M	0.94	5.74 million shs	4.25 million shs
FATE Fate Therapeutics	$1.07 -2.7%	$1.22	$0.66 ▼ $4.66	$126.06M	2.24	1.32 million shs	767,002 shs
ORKA Oruka Therapeutics	$13.60 +0.1%	$12.82	$5.49 ▼ $52.32	$508.82M	-0.35	159,251 shs	142,850 shs
SLDB Solid Biosciences	$6.83 -0.1%	$5.06	$2.41 ▼ $10.37	$530.21M	2.43	1.46 million shs	1.15 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	-0.42%	-19.38%	-10.98%	+30.56%	+137.37%
FATE Fate Therapeutics	-2.73%	-13.71%	-4.46%	-18.32%	-79.92%
ORKA Oruka Therapeutics	+0.07%	-4.56%	+7.85%	+26.98%	+1,359,999,900.00%
SLDB Solid Biosciences	-0.15%	-2.43%	+40.25%	+58.47%	-23.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.5613 of 5 stars	3.6	1.0	0.0	3.8	1.7	0.6
FATE Fate Therapeutics	3.9551 of 5 stars	3.1	2.0	4.7	3.2	1.7	0.6
ORKA Oruka Therapeutics	2.2575 of 5 stars	3.6	0.0	0.0	1.1	2.5	0.6
SLDB Solid Biosciences	2.6478 of 5 stars	4.6	1.0	0.0	1.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.14	Buy	$20.20	329.79% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	258.26% Upside
ORKA Oruka Therapeutics	3.20	Buy	$40.38	196.88% Upside
SLDB Solid Biosciences	3.17	Buy	$15.10	121.08% Upside

Current Analyst Ratings Breakdown

Latest FATE, ORKA, ATYR, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2025	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
7/21/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$16.00
7/21/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$40.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$230K	1,818.70	N/A	N/A	$0.83 per share	5.66
FATE Fate Therapeutics	$13.63M	9.00	N/A	N/A	$2.80 per share	0.38
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$10.84 per share	N/A
SLDB Solid Biosciences	$8.09M	65.44	N/A	N/A	$3.43 per share	1.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.81	N/A	N/A	N/A	N/A	-87.09%	-64.77%	8/12/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
ORKA Oruka Therapeutics	-$83.72M	-$4.51	N/A	N/A	N/A	N/A	-25.66%	-23.39%	8/7/2025 (Estimated)
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)

Latest FATE, ORKA, ATYR, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.34	N/A	N/A	N/A	$1.16 million	N/A
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.48	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/14/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	N/A	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/7/2025	Q1 2025	ATYR aTyr Pharma	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	7.79	7.79
FATE Fate Therapeutics	N/A	8.81	8.81
ORKA Oruka Therapeutics	N/A	30.03	30.03
SLDB Solid Biosciences	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
FATE Fate Therapeutics	97.54%
ORKA Oruka Therapeutics	56.44%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
FATE Fate Therapeutics	5.51%
ORKA Oruka Therapeutics	24.69%
SLDB Solid Biosciences	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	89.00 million	85.71 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
ORKA Oruka Therapeutics	N/A	37.44 million	28.20 million	N/A
SLDB Solid Biosciences	100	77.51 million	76.04 million	Optionable

FATE, ORKA, ATYR, and SLDB Headlines

Recent News About These Companies

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1 at 8:00 AM | globenewswire.com

Solid Bio Green on Fast Track Nod

July 23, 2025 | baystreet.ca

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

July 23, 2025 | globenewswire.com

Solid Biosciences (NASDAQ:SLDB) Trading 13.3% Higher - Should You Buy?

July 19, 2025 | marketbeat.com

What is HC Wainwright's Estimate for SLDB FY2027 Earnings?

July 16, 2025 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Buy" from Analysts

July 16, 2025 | marketbeat.com

SLDB - Solid Biosciences Inc Executives - Morningstar

July 15, 2025 | morningstar.comM

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

July 10, 2025 | prnewswire.com

SLDB Solid Biosciences Inc. - Seeking Alpha

July 10, 2025 | seekingalpha.com

Solid Biosciences receives FDA approval for CPVT gene therapy IND

July 10, 2025 | investing.com

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular ... - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT

July 10, 2025 | msn.com

Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes

July 9, 2025 | msn.com

SLDB - Solid Biosciences Inc Price vs Fair Value - Morningstar

July 8, 2025 | morningstar.comM

Solid Biosciences Inc. (SLDB) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

SLDB - Solid Biosciences Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

Solid Biosciences Inc. (SLDB) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Solid Biosciences (SLDB) with Buy Recommendation

June 26, 2025 | msn.com

Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences

...

June 18, 2025 | marketbeat.com

Solid Biosciences Approves Equity Plan Amendment at Meeting

June 13, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE, ORKA, ATYR, and SLDB Company Descriptions

aTyr Pharma NASDAQ:ATYR

$4.70 -0.02 (-0.42%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.73 +0.03 (+0.72%)

As of 08/1/2025 07:55 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Fate Therapeutics NASDAQ:FATE

$1.07 -0.03 (-2.73%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$1.06 -0.01 (-0.47%)

As of 08/1/2025 07:16 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Oruka Therapeutics NASDAQ:ORKA

$13.60 +0.01 (+0.07%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$13.60 0.00 (0.00%)

As of 08/1/2025 06:04 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Solid Biosciences NASDAQ:SLDB

$6.83 -0.01 (-0.15%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$6.64 -0.19 (-2.71%)

As of 08/1/2025 06:33 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time